Among the upcoming target agents, poziotinib demonstrated promising activity in a Phase II trial that enrolled pretreated NSCLC patients with EGFR exon 20 mutation (excluding acquired T790M). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.